Haojun Jia is the co-founder and CEO of Deep Principle, an AI-for-science startup building AI scientists that discover new materials and chemical reactions. He hatched the idea while finishing a physical chemistry PhD at MIT, where his research paired high-throughput quantum chemistry with machine learning to design catalysts. Deep Principle's platform - marketed as ReactiveAI and now the agentic tool Agent Mira - fuses deep learning with first-principles physics to compress the time and cost of materials R&D. The company has raised roughly $28 million across two rounds from investors including GL Ventures, Linear Capital, Vertex Ventures, and funds backed by Lenovo and Baidu. Jia was named to the Forbes 30 Under 30 Asia 2025 list in Healthcare & Science.
Huafeng Xu is the founder and CEO of Fathom Therapeutics (formerly AtomMap), a New York drug-design company that simulates protein motion at atomic resolution to design small molecules that work inside living cells. A computational chemist with 25+ years and 10,000+ citations, Xu spent 12 years at D. E. Shaw Research building the free-energy and molecular-dynamics methods now standard across pharma, then served as CTO of Silicon Therapeutics and Roivant Discovery before launching his own company. In April 2026 Fathom closed an oversubscribed $47M Series A led by Sutter Hill Ventures to scale its Microcosmos engine.
Aaron Sisto is the Co-Founder & CEO of Chronicle Studios, a content intelligence platform that uses proprietary agentic AI to help creators launch and scale global IP franchises. A PhD quantum chemist turned deep-tech investor turned entertainment entrepreneur, Sisto blends hard science and pop culture instincts in a company that raised an oversubscribed $11.6M seed round in 2025 backed by Patron and Point72 Ventures. Previously a partner at First Spark Ventures and Director of Engineering at Schmidt Futures, he co-founded Chronicle alongside entertainment veteran Chris deFaria, former president of DreamWorks Animation.